Spironolactone
- Generic Name
- Spironolactone
- Brand Names
- Aldactazide, Aldactone, Carospir, Qaialdo
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32O4S
- CAS Number
- 52-01-7
- Unique Ingredient Identifier
- 27O7W4T232
- Background
Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered. It is indicated to treat several ...
- Indication
Spironolactone is indicated for the treatment of the following conditions:
As spironolactone has antiandrogenic activity, its off-label uses include the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.
- Associated Conditions
- Edema, Hypertension, Primary Aldosteronism, Primary Hyperaldosteronism, Secondary hyperaldosteronism, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Idiopathic hyperaldosteronism, Refractory Edema
- Associated Therapies
- Perioperative drug treatment, Maintenance therapy
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
- Conditions
- Interventions
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2019-10-07
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 52
- Registration Number
- NCT02354352
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸The Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Mattel Children's Hospital and David Geffen School of Medicine at UCLA, Los Angeles, California, United States
Early Aldosterone Blockade in Acute Heart Failure: An Exploratory Safety Study
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- Indiana University
- Registration Number
- NCT02299726
Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial
- First Posted Date
- 2014-11-07
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 129
- Registration Number
- NCT02285920
- Locations
- 🇺🇸
Kidney Research Institute, University of Washington, Seattle, Washington, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Tissue Sodium in Pre-hypertensive Patients
- Conditions
- Interventions
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2019-05-22
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 71
- Registration Number
- NCT02236520
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Duke University
- Target Recruit Count
- 360
- Registration Number
- NCT02235077
- Locations
- 🇺🇸
Southeastern Regional Medical Center, Lumberton, North Carolina, United States
🇺🇸Metro Health System, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Biomarker Guided Therapies in Stage A/B Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2022-10-21
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 58
- Registration Number
- NCT02230891
- Locations
- 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States
A Study of LY2623091 in Participants With High Blood Pressure
- Conditions
- Interventions
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 304
- Registration Number
- NCT02194465
- Locations
- 🇺🇸
Cor Clinical Research LLC, Oklahoma City, Oklahoma, United States
🇵🇷Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico
🇺🇸Mountain View Clinical Research, Inc, Greer, South Carolina, United States
Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Trial
- First Posted Date
- 2014-06-20
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 79
- Registration Number
- NCT02169089
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Search of Biomarkers of Mineralocorticoid Receiver Activity : the Value of Neutrophil Gelatinase Associated Lipocalin (NGAL)in Serum or Urine in Human
- Conditions
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2014-05-02
- Lead Sponsor
- Central Hospital, Nancy, France
- Target Recruit Count
- 42
- Registration Number
- NCT02129621
- Locations
- 🇫🇷
Brabois Hospital, Nancy, France
🇫🇷Unit of arterial high blood pressure of the Georges Pompidou Hospital, Paris, France
🇫🇷Georges Pompidou Hospital, Paris, France
Spironolactone Against Anthracycline-induced Cardiomyopathy
- Conditions
- Interventions
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- TC Erciyes University
- Target Recruit Count
- 90
- Registration Number
- NCT02053974
- Locations
- 🇹🇷
Erciyes University School of Medicine, Kayseri, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.